In August 2022, BrainVectis, a subsidiary of AskBio, gained approval from the French National Agency for Safety of Medicines and Health Products (ANSM) to conduct a phase 1/2 trial with a drug called BV-101.
The trial will look at the safety and efficacy (ability to produce the desired result) of BV-101 in adult patients with early-stage Huntington’s Disease. BV-101 will be given (one time) through MRI-guided neurosurgical techniques directed to target tissues in the basal structures of the brain. In preclinical studies in mice, BV-101 showed the ability to repair the essential cholesterol pathway (which is damaged in HD patients), provide neuroprotection, and restore neuronal function by delivering a crucial enzyme in the brain which is lowered in people with Huntington’s Disease.
The trial will be in 2 parts with approximately 12-18 participants. One part is to find the correct dose and 2nd part, expansion of the trial. The exact number of participants will depend on the safety of part 1. This trial is called an open-label, meaning there is no placebo group. The participants will be rigorously monitored for 52 weeks and follow up of 4 years and is expected to take place in two sites in France.
18 Years to 65 Years (Adult, Older Adult)
Accepts Healthy Volunteers:
- Documented genetic confirmation of pathological CAG expansion in the huntingtin gene ≥40.
- Early manifest HD as defined by a UHDRS total functional capacity (TFC) score of 9 to 13 and a diagnostic classification level (DCL) of 4, or a DCL of 3 if present with cognitive impairment and clear evidence of disease progression.
- Striatal MRI volumes per hemisphere: Putamen ≥ 2.3 cm3 (per side); Caudate ≥ 1.7 cm3 (per side) on Screening MRI.
- All HD concomitant medications stable for at least 30 days prior to screening at the investigator’s discretion.
- Prior or ongoing medical condition, physical findings, ECG findings, or laboratory abnormality that, in the investigator’s opinion, would impact subject’s safety and compliance with the study procedures.
- Metastatic neoplasms within the five years prior to screening.
- Presence of clinically relevant immunologic, hematologic, hepatic, cardiac, or renal disease at the time of screening as per investigator’s clinical judgment.
- Current untreated and unstable depressive disorder or a serious mood disorder requiring hospitalization.
- History of prior suicide attempt or imminent risk of self-harm based on investigator’s judgment or with a “yes” answer on item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS).
- Patients with history of confirmed stroke, known intracranial neoplasms, vascular malformations, or intracranial hemorrhage.
- Subjects not deemed suitable for the surgical procedure as per the Neurosurgeon’s judgment.
- Any history of gene therapy, cell transplantation or any other experimental brain surgery.
- Any RNA or DNA targeted HD specific investigational agents such as antisense oligonucleotides within 6 months prior to screening.
- Subjects unable to tolerate or unwilling to undergo multiple lumbar punctures.
- Participation in any clinical trial of an approved or non-approved investigational drug or intervention within 12 weeks or 5 half-lives whichever is longer prior to treatment.
Institut du Cerveau (ICM), Hôpital La Pitié Salpêtrière APHP
Address: Paris, Ile-de-France, France, 75013
Contact: Hortense Hurmic. firstname.lastname@example.org